

Genotype distributions of the significant SNPs in TF pathway genes across ER, PR, HR, and triple negative status.

ORs, 95% CI and *P*-values determined with respect to the risk allele (**bold**) using logistic regression (additive model). Alleles for the positive DNA strand (UCSC annotated) are shown.

Estrogen receptor (ER) status									
SNP	ER-negative cases (n)/ controls(n)	OR (95%CI)	<i>P</i>-value	ER-positive cases (n)/ controls (n)	OR (95%CI)	<i>P</i>-value	ER-negative cases(n)/ ER-positive cases(n)	OR (95%CI)	<i>P</i>-value
rs12120605 (F5)									
GG	40/244			202/244			40/202		
TG	19/59	2.03 (1.14-3.61)	0.016	64/59	1.4 (0.97-2.04)	0.075	19/64	1.4 (0.81-2.42)	0.228
TT	1/1			4/1			1/4		
rs6427202 (F5)									
TT	12/103			81/103			12/81		
CT	35/165	1.72 (1.12-2.64)	0.014	140/165	1.24 (0.97-1.58)	0.091	35/140	1.34 (0.89-2.03)	0.164
CC	13/38			49/38			13/49		
rs9332542 (F5)									
GG	31/124			139/124			31/139		
AG	27/155	1.56 (1.01-2.39)	0.044	105/155	1.23 (0.97-1.57)	0.089	27/105	1.23 (0.81-1.86)	0.327
AA	2/28			27/28			2/27		
rs6427199 (F5)									
GG	29/97			108/97			29/108		
AG	22/161	1.59 (0.99-2.54)	0.054	121/161	1.27 (0.99-1.64)	0.063	22/121	1.19 (0.76-1.85)	0.449
AA	8/48			39/48			8/39		
rs3093261 (F10)									
CC	10/118			88/118			10/88		
TC	39/137	1.62 (1.09-2.40)	0.018	123/137	1.26 (1.00-1.58)	0.048	39/123	1.26 (0.85-1.86)	0.254
TT	11/51			61/51			11/61		
rs2069948 (EPCR)									
TT	19/118			78/118			19/78		
TC	33/125	1.00 (0.68-1.46)	0.998	129/125	1.27 (1.01-1.58)	0.038	33/129	0.77 (0.87-1.93)	0.208
CC	8/62			63/62			8/63		

Progesterone receptor (PR) status

SNP	PR-negative cases (n)/ controls(n)	OR (95%CI)	P-value	PR-positive cases (n)/ controls (n)	OR (95%CI)	P-value	PR-negative cases(n)/ PR-positive cases(n)	OR (95%CI)	P-value
rs12120605 (F5)									
GG	67/244			175/244			67/175		
TG	30/59	1.96 (1.21-3.16)	0.006	53/59	1.33 (0.90-1.97)	0.150	30/53	1.44 (0.90-2.31)	0.131
TT	2/1			3/1			2/3		
rs6427202 (F5)									
TT	22/103			71/103			22/71		
CT	57/165	1.57 (1.11-2.24)	0.011	118/165	1.22 (0.94-1.58)	0.135	57/118	1.26 (0.89-1.78)	0.197
CC	20/38			42/38			20/42		
rs9332542 (F5)									
GG	53/124			117/124			53/117		
AG	39/155	1.73 (1.21-2.47)	0.003	93/155	1.14 (0.89-1.47)	0.296	39/93	1.45 (1.02-2.06)	0.039
AA	6/28			23/28			6/23		
rs6427199 (F5)									
GG	49/97			88/97			49/88		
AG	39/161	1.55 (1.06-2.27)	0.023	104/161	1.25 (0.95-1.63)	0.107	39/104	1.2 (0.83-1.75)	0.330
AA	10/48			37/48			10/37		
rs3093261 (F10)									
CC	23/118			75/118			23/75		
TC	57/137	1.44 (1.04-1.99)	0.028	105/137	1.27 (1.00-1.61)	0.048	57/105	1.11 (0.80-1.55)	0.527
TT	19/51			53/51			19/53		
rs2069948 (EPCR)									
TT	32/118			65/118			32/65		
TC	52/125	1.02 (0.75-1.40)	0.888	110/125	1.30 (1.03-1.65)	0.025	52/110	0.77 (0.55-1.07)	0.120
CC	15/62			56/62			15/56		

Hormone receptor negative status (ER negative/PR negative)

SNP	ER/PR negative cases(n)/controls(n)	OR (95%CI)	P-value	ER/PR negative cases(n)/other cases(n)*	OR (95%CI)	P-value
rs12120605 (F5)						
GG	39/244			39/203		
TG	18/59	1.99 (1.11-3.56)	0.021	18/65	1.36 (0.78-2.37)	0.275
TT	1/1			1/4		
rs6427202 (F5)						
TT	11/103			11/82		
CT	35/165	1.73 (1.12-2.67)	0.014	35/140	1.34 (0.88-2.04)	0.171
CC	12/38			12/50		
rs9332542 (F5)						
GG	30/124			30/140		
AG	26/155	1.54 (0.99-2.37)	0.053	26/106	1.18 (0.75-1.86)	0.463
AA	2/28			2/27		
rs6427199 (F5)						
GG	28/97			28/109		
AG	21/161	1.58 (0.98-2.55)	0.058	21/122	1.21 (0.80-1.84)	0.369
AA	8/48			8/39		
rs3093261 (F10)						
CC	10/118			10/88		
TC	37/137	1.61 (1.08-2.41)	0.020	37/125	1.26 (0.84-1.87)	0.261
TT	11/51			11/61		
rs2069948 (EPCR)						
TT	18/118	1.02 (0.70-1.50)	0.915	18/79	1.26 (0.84-1.88)	0.269
TC	32/125			32/130		
CC	8/62			8/63		

*Cases with either ER negative/PR positive, ER positive/PR negative or ER positive/PR positive status

Triple negative status (ER negative/PR negative/HER2 negative)

SNP	ER/PR/HER2 negative cases(n)/ controls(n)	OR (95%CI)	P-value	ER/PR negative cases(n)/ other cases(n)*	OR (95%CI)	P-value
rs12120605 (F5)						
GG	33/244			33/209		
TG	16/59	2.11 (1.14-3.89)	0.017	16/67	1.44 (0.81-2.58)	0.216
TT	1/1			1/4		
rs6427202 (F5)						
TT	9/103			9/84		
CT	29/165	1.90 (1.19-3.02)	0.007	29/146	1.48 (0.95-2.32)	0.084
CC	12/38			12/50		
rs9332542 (F5)						
GG	28/124			28/142		
AG	21/155	1.68 (1.05-2.68)	0.032	21/111	1.41 (0.86-2.31)	0.179
AA	1/28			1/28		
rs6427199 (F5)						
GG	26/97			26/111		
AG	16/161	1.88 (1.11-3.19)	0.018	16/127	1.33 (0.84-2.09)	0.223
AA	7/48			7/40		
rs3093261 (F10)						
CC	10/118			10/88		
TC	32/137	1.44 (0.94-2.19)	0.095	32/130	1.09 (0.72-1.67)	0.680
TT	8/51			8/64		
rs2069948 (EPCR)						
TT	16/118			16/81		
TC	28/125	1.03 (0.68-1.55)	0.883	28/134	1.33 (0.87-2.06)	0.191
CC	6/62			6/65		

*Cases with either ER negative/PR positive/HER2 positive, ER negative/PR positive/HER2 negative, ER positive/PR negative/HER2 positive, ER positive/PR negative/HER2 negative, ER positive/PR positive/Her2 positive, ER positive/PR positive/Her2 negative, ER negative/PR negative/HER2 positive status.